Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

January 1, 2028

Conditions
Vascular Ehlers-Danlos Syndrome
Interventions
OTHER

Heartmath Intervention

The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. During the initial visit for the intervention group the same assessment will be included, however, they will also receive 10-15 of instruction on a basic Heartmath technique. Group participants will be asked to complete 5-10 minutes of HeartMath techniques 2x daily. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. However, each week the intervention group will receive an addition 10-15 minutes of training and advancement on HeartMath techniques as well as continued written and video reinforcement.

OTHER

Control Group

The participants will all complete baseline surveys and paperwork including signed consent, psychometric surveys, demographic survey, and a brief, open-ended questionnaire about their feelings about living with VEDS. The initial visit will include an HRV assessment using the HeartMath sensor via the 3-step Protocol developed by the HeartMath Institute. Participants from both groups will have weekly virtual sessions that include the 3-step Protocol HRV assessment. After the CG has completed 8 weeks, they will then have access to materials related to the techniques that were taught to the HMI group to allow for therapeutic equality.

Trial Locations (1)

77030

RECRUITING

Texas Children's Hospital, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Southern Star Research

INDUSTRY

lead

Baylor College of Medicine

OTHER

NCT05994664 - Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients | Biotech Hunter | Biotech Hunter